Atlas Trials

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Clinical trial NCT05032183 · TERMINATED

Trial details

NCT number
NCT05032183
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Adult Lymphoblastic LymphomaRecurrent B Acute Lymphoblastic LeukemiaRecurrent T Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Lymphoblastic LymphomaRefractory T Acute Lymphoblastic Leukemia
Start date
2022-02-17
Primary completion
2024-07-31
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.